Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma.

Journal Article (Journal Article)

Natural killer/T-cell lymphoma (NKTCL) is a rare subtype of non-Hodgkin lymphoma that is associated with a poor outcome. Currently, the treatment needs of NKTCL remain unmet, and efforts to further improve treatment are urgently needed. Herein, seven patients with NKTCL who failed to respond to various types of chemotherapies were treated with the anti-programmed death 1 (anti-PD-1) antibody pembrolizumab at 100 mg every 3 weeks. After a median of four cycles of treatment (range 2-18), four out of seven patients responded (two complete response, two partial response, overall response rate 57%). Expression of PD1-ligand available was 50, 20, 30, 70, and 30% of five patients respectively. It is negative in one patient and not tested in one patient. Adverse events, which mostly ranged from grade I to grade III, were tolerable and could be safely handled, although immune-related pneumonitis was notable. Overall, PD-1 blockade with pembrolizumab represents a favorable strategy for the treatment of refractory/relapsed NKTCL.

Full Text

Duke Authors

Cited Authors

  • Li, X; Cheng, Y; Zhang, M; Yan, J; Li, L; Fu, X; Zhang, X; Chang, Y; Sun, Z; Yu, H; Zhang, L; Wang, X; Wu, J; Li, Z; Nan, F; Tian, L; Li, W; Young, KH

Published Date

  • January 31, 2018

Published In

Volume / Issue

  • 11 / 1

Start / End Page

  • 15 -

PubMed ID

  • 29386072

Pubmed Central ID

  • PMC5793390

Electronic International Standard Serial Number (EISSN)

  • 1756-8722

Digital Object Identifier (DOI)

  • 10.1186/s13045-018-0559-7


  • eng

Conference Location

  • England